297 related articles for article (PubMed ID: 35454037)
21. Heart Failure With Reduced Ejection Fraction: A Review.
Murphy SP; Ibrahim NE; Januzzi JL
JAMA; 2020 Aug; 324(5):488-504. PubMed ID: 32749493
[TBL] [Abstract][Full Text] [Related]
22. Sodium-glucose cotransporter-2 inhibitors in heart failure: Potential decongestive mechanisms and current clinical studies.
Biegus J; Fudim M; Salah HM; Heerspink HJL; Voors AA; Ponikowski P
Eur J Heart Fail; 2023 Sep; 25(9):1526-1536. PubMed ID: 37477086
[TBL] [Abstract][Full Text] [Related]
23. Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases.
Komuro I; Kadowaki T; Bodegård J; Thuresson M; Okami S; Yajima T
Diabetes Obes Metab; 2021 Apr; 23 Suppl 2():19-27. PubMed ID: 33835641
[TBL] [Abstract][Full Text] [Related]
24. Potential Benefits of Sodium-Glucose Transporter-2 Inhibitors in the Symptomatic and Functional Status of Patients With Heart Failure: A Systematic Review and Meta-Analysis.
Bhalla S; AlQabandi Y; Nandula SA; Boddepalli CS; Gutlapalli SD; Lavu VK; Abdelwahab Mohamed Abdelwahab R; Huang R; Potla S; Hamid P
Cureus; 2022 Sep; 14(9):e29579. PubMed ID: 36312657
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Implications of Congestion on Physical Examination Among Contemporary Patients With Heart Failure and Reduced Ejection Fraction: PARADIGM-HF.
Selvaraj S; Claggett B; Pozzi A; McMurray JJV; Jhund PS; Packer M; Desai AS; Lewis EF; Vaduganathan M; Lefkowitz MP; Rouleau JL; Shi VC; Zile MR; Swedberg K; Solomon SD
Circulation; 2019 Oct; 140(17):1369-1379. PubMed ID: 31510768
[TBL] [Abstract][Full Text] [Related]
26. Impact of SGLT2 inhibitors on cardiovascular outcomes in patients with heart failure with reduced ejection fraction.
Starr JA; Pinner NA; Lisenby KM; Osmonson A
Pharmacotherapy; 2021 Jun; 41(6):526-536. PubMed ID: 33866578
[TBL] [Abstract][Full Text] [Related]
27. Phenotyping congestion in patients with acutely decompensated heart failure with preserved and reduced ejection fraction: The Decongestion duRing therapY for acute decOmpensated heart failure in HFpEF vs HFrEF- DRY-OFF study.
Cogliati C; Ceriani E; Gambassi G; De Matteis G; Perlini S; Perrone T; Muiesan ML; Salvetti M; Leidi F; Ferrara F; Sabbà C; Suppressa P; Fracanzani A; Montano N; Fiorelli E; Tripepi G; Gori M; Pitino A; Pietrangelo A
Eur J Intern Med; 2022 Mar; 97():69-77. PubMed ID: 34844795
[TBL] [Abstract][Full Text] [Related]
28. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
Ikonomidis I; Pavlidis G; Thymis J; Birba D; Kalogeris A; Kousathana F; Kountouri A; Balampanis K; Parissis J; Andreadou I; Katogiannis K; Dimitriadis G; Bamias A; Iliodromitis E; Lambadiari V
J Am Heart Assoc; 2020 May; 9(9):e015716. PubMed ID: 32326806
[TBL] [Abstract][Full Text] [Related]
29. Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion.
Van Aelst LNL; Arrigo M; Placido R; Akiyama E; Girerd N; Zannad F; Manivet P; Rossignol P; Badoz M; Sadoune M; Launay JM; Gayat E; Lam CSP; Cohen-Solal A; Mebazaa A; Seronde MF
Eur J Heart Fail; 2018 Apr; 20(4):738-747. PubMed ID: 29251818
[TBL] [Abstract][Full Text] [Related]
30. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
Aguilar-Gallardo JS; Correa A; Contreras JP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
[TBL] [Abstract][Full Text] [Related]
31. Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
Kato ET; Silverman MG; Mosenzon O; Zelniker TA; Cahn A; Furtado RHM; Kuder J; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Bonaca MP; Ruff CT; Desai AS; Goto S; Johansson PA; Gause-Nilsson I; Johanson P; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
Circulation; 2019 May; 139(22):2528-2536. PubMed ID: 30882238
[TBL] [Abstract][Full Text] [Related]
32. Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Zhang A; Luo X; Meng H; Kang J; Qin G; Chen Y; Zhang X
Front Endocrinol (Lausanne); 2020; 11():604250. PubMed ID: 33519713
[TBL] [Abstract][Full Text] [Related]
33. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data.
Khunti K; Kosiborod M; Kim DJ; Kohsaka S; Lam CSP; Goh SY; Chiang CE; Shaw JE; Cavender MA; Tangri N; Franch-Nadal J; Holl RW; Jørgensen ME; Norhammar A; Eriksson JG; Zaccardi F; Karasik A; Magliano DJ; Thuresson M; Chen H; Wittbrodt E; Bodegård J; Surmont F; Fenici P;
Cardiovasc Diabetol; 2021 Jul; 20(1):159. PubMed ID: 34332558
[TBL] [Abstract][Full Text] [Related]
34. Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction?
Singh AK; Singh R; Misra A
J Diabetes; 2021 Jul; 13(7):596-600. PubMed ID: 33792199
[TBL] [Abstract][Full Text] [Related]
35. What Makes Sodium-Glucose Co-Transporter-2 Inhibitors Stand out in Heart Failure?
Khan MS; Vaduganathan M
Curr Diab Rep; 2020 Oct; 20(11):63. PubMed ID: 33040170
[TBL] [Abstract][Full Text] [Related]
36. Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients having reduced ejection fraction heart failure with type 2 diabetes, prediabetes and normoglycemia?
Singh AK; Singh R
Diabetes Metab Syndr; 2021; 15(6):102282. PubMed ID: 34562869
[TBL] [Abstract][Full Text] [Related]
37. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL.
Cavender MA; Norhammar A; Birkeland KI; Jørgensen ME; Wilding JP; Khunti K; Fu AZ; Bodegård J; Blak BT; Wittbrodt E; Thuresson M; Fenici P; Hammar N; Kosiborod M;
J Am Coll Cardiol; 2018 Jun; 71(22):2497-2506. PubMed ID: 29852973
[TBL] [Abstract][Full Text] [Related]
38. Sodium Glucose Cotransporter Type 2 Inhibitors Improve Cardiorenal Outcome of Patients With Coronary Artery Disease: A Meta-Analysis.
Wei W; Liu J; Chen S; Xu X; Guo D; He Y; Huang Z; Wang B; Huang H; Li Q; Chen J; Chen H; Tan N; Liu Y
Front Endocrinol (Lausanne); 2022; 13():850836. PubMed ID: 35330914
[TBL] [Abstract][Full Text] [Related]
39. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
[TBL] [Abstract][Full Text] [Related]
40. Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review.
Georgiou P; Shi W; Serhiyenia T; Akram A; Proute MC; Pradeep R; Kerolos ME; Khan S
Cureus; 2021 Oct; 13(10):e18485. PubMed ID: 34754647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
